A report commissioned by Pharmaceutical Research and Manufacturers of America (PhRMA), the trade group representing big pharma in the USA, has highlighted the role of post-approval research and development (R&D) in advancing cancer treatment options.
This research has delivered unprecedented progress in the fight against cancer over the past 10 years, according to PhRMA.
The report builds off previous research that shows for certain cancer medicines, most of the high-impact clinical research happens after a medicine is initially approved.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze